Prestige Consumer Healthcare Inc. has priced a private offering of $400 million in aggregate principal amount of 6.25% senior notes due 2034. The notes are senior unsecured obligations of its wholly-owned subsidiary, Prestige Brands, Inc., and are guaranteed by the company and certain domestic subsidiaries. The company intends to use the net proceeds from the offering, combined with cash on hand, to redeem all $400 million of Prestige’s outstanding 5.125% Senior Notes due January 2028 and to pay related fees and expenses. The sale of the notes is expected to be completed on or about July 15, 2026, subject to customary closing conditions.

The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended, or to non-U.S. persons in compliance with Regulation S. The notes have not been registered under the Securities Act or any other jurisdiction's securities laws and may not be offered or sold in the United States without registration or an applicable exemption.

Key Details of the Offering

Prestige Consumer Healthcare markets, sells, manufactures, and distributes consumer healthcare products to retail outlets in the U.S., Canada, Australia, and other international markets. The company’s portfolio includes brands such as Breathe Right, Monistat, Summer’s Eve, BC, Goody’s, Clear Eyes, TheraTears, DenTek, Dramamine, Fleet, Chloraseptic, Luden’s, Compound W, Little Remedies, Boudreaux’s Butt Paste, Nix, Debrox, Gaviscon, Hydralyte, and Fess.

Prestige Consumer Healthcare Inc. saw its shares fall over 11% on May 14, 2026, after the company revealed significant revenue declines and production problems driving its disappointing Q4 2026 financial results. The drop was triggered by a 5% year-over-year revenue decline and a 6.4% sequential decrease, with notable weakness in its North America OTC Eye & Ear Care and International OTC segments. The company's Clear Eyes® brand, a major product line, faced supply chain constraints due to issues at its recently acquired Pillar5 facility.

Investigation Launched

National shareholder rights firm Hagens Berman has opened an investigation into whether Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints before May 14, 2026. The firm is examining whether the company violated federal securities laws by failing to disclose the extent of the Pillar5 facility's performance issues. Reed Kathrein, the Hagens Berman partner leading the investigation, stated the focus is on when Prestige and its management first became aware of the facility's underperformance and whether investors were misled about progress in resolving Clear Eyes® supply issues.

Financial Performance Breakdown

The Q4 2026 results highlighted significant declines across key segments:

During the earnings call on May 14, 2026, management attributed the declines to "Clear Eyes supply constraints" and unexpected shutdowns at the Pillar5 facility. The company had previously touted the facility as a solution to persistent supply chain issues and a means to restore Clear Eyes® to its leading market share position.

Market Reaction

The market reacted swiftly to the news, sending Prestige shares significantly lower. Hagens Berman is encouraging investors who suffered substantial losses to submit their claims for potential recovery. The firm is also seeking whistleblowers with non-public information about Prestige's practices to assist in the investigation or participate in the SEC Whistleblower program, which offers rewards of up to 30% of successful SEC recoveries.